Hemetron AG

Today, treatment decisions for more than 100 million patients with inflammatory rheumatic diseases are constrained by the need for doctor visit-based blood testing, typically performed only once every three months. Hemetron is transforming chronic disease management by introducing the first quantitative at-home inflammation test, for weekly testing with results shared digitally with physicians. By integrating clinically actionable blood data into the digital health ecosystem, we close a critical gap in chronic care, enabling remote patient management for better patient outcomes at lower cost.